来自官方财务报表的收入、利润与现金流历史。
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $2.9B | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B | $3.8B | $2.9B | $2.8B | $2.3B | $2.1B | $2.1B | $2.2B | $2.2B | $2.1B | $1.9B | $1.7B | $1.6B | $2.0B | $1.8B | $1.5B |
| 毛利 | $1.5B | $1.5B | $1.3B | $1.3B | $1.8B | $2.3B | $2.0B | $1.3B | $1.3B | $1.0B | $972M | $930M | $971M | $940M | $924M | $824M | $740M | $699M | $835M | $715M | $623M |
| 毛利率% | 52.1% | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% | 44.8% | 45.0% | 45.6% | 46.0% | 44.2% | 43.4% | 43.4% | 43.7% | 42.9% | 43.4% | 45.1% | 42.6% | 40.0% | 40.3% |
| 营业利润（EBIT） | $358M | $357M | $411M | $399M | $781M | $1.3B | $1.0B | $405M | $371M | $305M | $306M | $267M | $230M | $259M | $201M | $118M | $173M | $140M | $201M | $175M | $152M |
| 营业利润率% | 12.3% | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 27.0% | 14.1% | 13.4% | 13.5% | 14.4% | 12.7% | 10.3% | 11.9% | 9.5% | 6.1% | 10.1% | 9.0% | 10.3% | 9.8% | 9.8% |
| 净利 | $238M | $242M | $296M | ($118M) | $569M | $943M | $728M | $228M | $239M | $113M | $234M | $212M | $158M | $168M | $68M | $1M | $384M | $86M | $128M | $133M | $117M |
| 净利润率 % | 8.2% | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 5.0% | 11.1% | 10.1% | 7.1% | 7.8% | 3.2% | 0.1% | 22.5% | 5.5% | 6.6% | 7.4% | 7.6% |
| EBITDA | — | $663M | $840M | $714M | $1.2B | $1.6B | $1.2B | $515M | $505M | $446M | $386M | $352M | $323M | $332M | $223M | $200M | $267M | $201M | $263M | $245M | $229M |
| 每股收益（EPS） | $2.09 | $2.13 | $2.41 | $-0.95 | $4.50 | $8.08 | $6.50 | $2.04 | $2.14 | $1.02 | $2.12 | $1.87 | $1.39 | $1.48 | $0.60 | $0.01 | $3.25 | $0.73 | $1.08 | $1.10 | $0.93 |
| 已发行股数 (M) | — | 113M | 123M | 125M | 126M | 117M | 112M | 112M | 112M | 111M | 110M | 113M | 114M | 114M | 115M | 114M | 118M | 117M | 119M | 121M | 126M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 RVTY 交互式查看器。 /companies/us/RVTY
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms